SCHEMBL20649264

SCHEMBL20649264

CCOC(=O)c1sc(NC(=O)c2n[nH]c3c2C(C)(C)Cc2cnc(N)nc2-3)nc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.44
NPC1 O15118 8/20 0.44
RAB9A P51151 7/20 0.44
HPGD P15428 5/20 0.44
KDM4E B2RXH2 6/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 8/20 0.43
TP53 P04637 2/20 0.43
RXFP1 Q9HBX9 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
POLB P06746 2/20 0.42
KLF5 Q13887 1/20 0.42
HSP90AA1 P07900 1/20 0.42
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CASP3 P42574 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30183619 1.00 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL30183945 0.89 PKM (0.37) SMN1; SMN2NPC1RAB9AKDM4EHTT
SCHEMBL20649012 0.89 PKM (0.37) SMN1; SMN2NPC1RAB9AKDM4EHTT
SCHEMBL20649253 0.88 CDK4 (0.37) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL30183518 0.88 CDK4 (0.37) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL20648952 0.86 RAB9A (0.44) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL30183509 0.86 RAB9A (0.44) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL4171044 0.84 CDK4 (0.45) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL20649287 0.84 LMNA (0.47) NPC1RAB9AHPGDKDM4EALDH1A1
SCHEMBL30183520 0.84 LMNA (0.47) NPC1RAB9AHPGDKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110997678-B Pyrazoloquinazoline derivatives as choline kinase inhibitors 内尔维亚诺医疗科学公司 2023-02-21 CN disclosed
US-11117901-B2 Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-09-14 US disclosed
US-20200131188-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-04-30 US disclosed
CN-110997678-A Pyrazoloquinazoline derivatives as choline kinase inhibitors 内尔维亚诺医疗科学公司 2020-04-10 CN disclosed
WO-2019011715-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131188-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS CHKA, CHKB, NADK SMN1; SMN2 2117/4885NPC1 489/4885RAB9A 1097/4885
US-11117901-B2 Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors CHKA, CHKB, NADK SMN1; SMN2 1667/4885NPC1 371/4885RAB9A 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.